公开(公告)号：US20060258666A1

公开(公告)日：2006-11-16

申请号：US11407605

申请日：2006-04-20

Applicant: Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

Inventor： Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

IPC: A61K31/501 ,  A61K31/454 ,  A61K31/4439 ,  A61K31/4172 ,  C07D403/02

CPC classification number: C07D405/12 ,  C07D307/68 ,  C07D409/12

Abstract: The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Abstract translation: 本发明涉及式II的化合物：其中A，R 1，R 2，R 3，R 4， 说明书中列出了X，Y和W，以及其抑制蛋白酪氨酸激酶，特别是c-fms激酶的溶剂合物，水合物，互变异构体或其药学上可接受的盐。

公开(公告)号：US20050044093A1

公开(公告)日：2005-02-24

申请号：US10643031

申请日：2003-08-18

Applicant: Raymond Patch ,  Mathrubootham Janakiraman

Inventor： Raymond Patch ,  Mathrubootham Janakiraman

IPC: G06F9/45 ,  G06F17/00 ,  G06F17/21 ,  G06F17/22 ,  G06F17/27 ,  G06F17/30

CPC classification number: G06F17/2725 ,  G06F17/2247

Abstract: A mechanism for validating a message, such as an XML message or other hierarchically-organized content. A validation engine walks through the tree represented by the message preferably in depth-first traversal order. Upon encountering each node in the tree, the validation engine consults a validation table to identify a delegate that is to be invoked. The validation engine then invokes the delegate identified for that node, and calls itself recursively on the subtrees of the current node. After the subtrees have been processed, the validation engine again consults the validation table to identify a post-handler for the current node, and then invokes the post-handler. An entry in the validation table may be flagged as “exclusive” to prevent traversal of subtrees of the node corresponding to that entry. Additionally, there may be both global and local validation tables, where the global table is used when a node has no entry in the local table.

Abstract translation: 用于验证消息的机制，例如XML消息或其他分层组织的内容。 验证引擎优选地以深度优先遍历顺序遍历由消息表示的树。 遇到树中的每个节点时，验证引擎将查询验证表，以标识要调用的代理。 然后，验证引擎调用为该节点标识的委托，并在当前节点的子树上递归调用自身。 处理子树后，验证引擎再次查阅验证表，以识别当前节点的后处理程序，然后调用后处理程序。 验证表中的条目可以标记为“排他”，以防止与该条目相对应的节点的遍历遍历。 另外，可能有全局和局部验证表，其中当节点在本地表中没有条目时使用全局表。

公开(公告)号：US07846953B2

公开(公告)日：2010-12-07

申请号：US12043269

申请日：2008-03-06

Applicant: Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

Inventor： Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

IPC: A61K31/426 ,  C07D277/04

CPC classification number: C07D277/34 ,  C07D263/44

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖症，升高的血糖水平和胰岛素抵抗。

公开(公告)号：US20050113566A1

公开(公告)日：2005-05-26

申请号：US10970903

申请日：2004-10-22

Applicant: Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

Inventor： Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

IPC: A61K31/16 ,  A61K31/195 ,  A61K31/452 ,  A61K31/4545 ,  C07D223/12 ,  C07D265/30 ,  C07D279/12 ,  C07D307/68 ,  C07D405/12 ,  C07D409/12

CPC classification number: C07D405/12 ,  C07D307/68 ,  C07D409/12

Abstract: The invention relates to compounds of Formula I: wherein A is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORA, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; or a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; R1 is —H, aryl, —CORa, —CORa, —COORa, —CONRaRb, —SO2Ra or —SO2NRaRb; X is —CO—, —C(═NH)—, —CS—, —CON(Ra)—, —CS(NRa)—, —SO2— or —CRaRb—; Y is —S—, —SO—, —SO2—, —O— or direct link; R2 is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which may be optionally substituted with one or more halogens; and W is phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C1-4 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, —CF3, alkoxy, aryloxy, arylalkoxy, —OCF3, —CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —NHCORaRb, —NHSO2Ra, —NO2, —SORa, —SO3Ra or —SO2NRaRb; or a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with -C1-6 alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, —CF3, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, —OCF3, —OCO-alkyl, —OCO-alkylamino, —OCO-alkylamido, CORa, —CN, —C(NH)NH2, —COORa, —CONRaRb, —N(Ra)CORb, —NO2, —SO2Ra, —SO3Ra or —SO2NRaRb; as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.